Abstract
Background Though ischemic cardiomyopathy is the leading cause of heart failure (HF), most patients do not undergo coronary assessment after heart failure diagnosis. In a safety-net population, referral patterns have not been studied, and it is unknown whether coronary assessment is associated with improved HF outcomes.
Methods Using an electronic health record cohort of all individuals with HF within San Francisco Health Network from 2001-2019, we identified factors associated with completion of coronary assessment (invasive coronary angiography, nuclear stress, or coronary computed tomographic angiography). Then we emulated a randomized clinical trial of elective coronary assessment with outcomes of all-cause mortality and a composite outcome of mortality and emergent angiography. We used propensity scores to account for differences between groups. We used national death records to improve ascertainment of mortality.
Results Among 14,829 individuals with HF (median 62 years old, 5,855 [40%] women), 3,987 (26.9%) ever completed coronary assessment, with 2,467 (18.5%) assessed out of 13,301 with unknown CAD status at HF diagnosis. Women and older individuals were less likely to complete coronary assessment, with differences by race/ethnicity, medical history, substance use, housing, and echocardiographic findings. Among 5,972 eligible for inclusion in the “target trial,” 627 underwent early elective coronary assessment and 5,345 did not. Coronary assessment was associated with lower mortality (HR 0.84; 95% CI 0.72-0.97; p=0.025), reduced risk of the composite outcome, higher rates of revascularization, and higher use of medical therapy.
Conclusions In a safety-net population, disparities in coronary assessment after HF diagnosis are not fully explained by CAD risk factors. Our target trial emulation suggests coronary assessment is associated with improved HF outcomes possibly related to higher rates of revascularization and GDMT use, but with low certainty that this is finding is not attributable to unmeasured confounding.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
N/a
Funding Statement
Dr. Durstenfeld is funded by NIH grant NIH/NLBI (K12 HL143961). This study was funded by internal funds from the Division of Cardiology at Zuckerberg San Francisco General and was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1TR001872. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval was granted by the University of California with a waiver of informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosures: None of the authors have pertinent disclosures or relevant conflicts of interest.
Funding: Dr. Durstenfeld is funded by NIH grant NIH/NLBI (K12 HL143961). This study was funded by internal funds from the Division of Cardiology at Zuckerberg San Francisco General and was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1TR001872. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Abbreviations: HF=heart failure; HFrEF=Heart failure with reduced ejection fraction; HFpEF=Heart failure with preserved ejection fraction; CAD=Coronary Artery Disease; CABG= coronary artery bypass graft; SFHN=San Francisco Health Network; GDMT=guideline directed medical therapy; left ventricular ejection fraction (LVEF); left ventricular (LV); CCTA=coronary computed tomographic angiography; ACE-I=Angiotensin converting enzyme inhibitor; ARB=angiotensin receptor blockers; ARNI=angiotensin receptor/neprilysin inhibitor; SGLT2i =sodium glucose cotransporter-2 inhibitor
Data Availability
The deidentified dataset will be made available upon reasonable request to the corresponding author.
